Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-23-0232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Chiara Alessandra Cella und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Zebrafish, Neuroendocrine Tumors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroendocrine tumors (NETs) are highly vascularized malignancies in which angiogenesis may entail cell proliferation and survival. Among the emerging compounds with antivascular properties, cabozantinib (CAB) appeared promising. We analyzed the antitumor activity of CAB against NETs utilizing in vitro and in vivo models. For cell cultures, we used BON-1, NCI-H727 and NCI-H720 cell lines. Cell viability was assessed by manual count coupled with quantification of cell death, performed through fluorescence-activated cell sorting analysis as propidium iodide exclusion assay. In addition, we investigated the modulation of the antiapoptotic myeloid cell leukemia 1 protein under CAB exposure, as a putative adaptive pro-survival mechanism, and compared the responses with sunitinib. The activity of CAB was also tested in mouse and zebrafish xenograft tumor models. Cabozantinib showed a dose-dependent and time-dependent effect on cell viability and proliferation in human NET cultures, besides a halting of cell cycle progression for endoduplication, never reported for other tyrosine kinase inhibitors. In a transplantable zebrafish model, CAB drastically inhibited NET-induced angiogenesis and migration of implanted cells through the embryo body. CAB showed encouraging activity in NETs, both in vitro and in vivo models. On this basis, we envisage future research to further investigate along these promising lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
- Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, Brescia, Italy.
- Department of Experimental Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
- Metal Targeted Therapy & Immunology lab, Childrens' cancer institute, Sydney, NSW, Australia.
- Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS, Istituto Auxologico Italiano, Milan, Italy.
- Laboratory of Endocrine and Metabolic Research, IRCCS, Istituto Auxologico Italiano, Milan, Italy.
ORCID-Profile: Chiara Alessandra Cella, Nicola Fazio, Giovanni Vitale
Zitieren
APA
Cella, C. A., Cazzoli, R., Fazio, N., De Petro, G., Gaudenzi, G., Carra, S., Romanenghi, M., Spada, F., Grossi, I., Pallavicini, I., Minucci, S., & Vitale, G. (2023). Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0232
Vancouver
Cella CA, Cazzoli R, Fazio N, De Petro G, Gaudenzi G, Carra S, et al. Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms. Endocrine-Related Cancer. 2023. doi:10.1530/erc-23-0232
BibTeX
@article{Cella2023,
author = {Cella, Chiara Alessandra and Cazzoli, Riccardo and Fazio, Nicola and De Petro, Giuseppina and Gaudenzi, Germano and Carra, Silvia and Romanenghi, Mauro and Spada, Francesca and Grossi, Ilaria and Pallavicini, Isabella and Minucci, Saverio and Vitale, Giovanni},
title = {Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-23-0232}
}
EUVIMED